300685 艾德生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)8.29916.32718.41619.21917.760
总资产报酬率 ROA (%)7.33414.58416.63617.03515.415
投入资产回报率 ROIC (%)8.01615.73917.94819.02415.740

边际利润分析
销售毛利率 (%)85.15383.96882.44984.37686.965
营业利润率 (%)29.49628.86934.15727.61527.752
息税前利润/营业总收入 (%)27.28525.77930.40428.25728.703
净利润/营业总收入 (%)26.49225.05831.38226.06524.757

收益指标分析
经营活动净收益/利润总额(%)100.665101.68862.94494.48388.045
价值变动净收益/利润总额(%)3.243-0.6780.6913.2990.611
营业外收支净额/利润总额(%)-1.102-2.167-0.552-0.500-0.716

偿债能力分析
流动比率 (X)7.9819.28813.9748.8456.737
速动比率 (X)7.8269.12313.6178.6076.594
资产负债率 (%)11.29411.9689.1589.88612.716
带息债务/全部投入资本 (%)2.6752.7402.9560.072--
股东权益/带息债务 (%)3,611.9023,524.0473,255.050137,476.032-21,966.057
股东权益/负债合计 (%)785.398735.583991.900908.205686.406
利息保障倍数 (X)-14.439-10.407-8.52736.23925.003

营运能力分析
应收账款周转天数 (天)179.489168.117188.285146.2880.000
存货周转天数 (天)69.02666.30279.28867.4690.000